-
Founded in:
2008-06-26 -
Country:
China -
Address:
No. 1503, Meishan Road, Economic and Technological Development Zone, Ma'anshan City, Anhui Province -
Tax NO.:
913405006758985090 -
Registered Funds:
145.5 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Adenosine5'-(tetrahydrogen triphosphate), disodiuM salt, trihydrate (9CI) |
It is a coenzyme that improves the body's metabolism and participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotides in the body. It is also the main source of energy in the body. When energy is needed for absorption, secretion, muscle contraction and biochemical synthesis reactions, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time. Animal experiments can inhibit the slow calcium ion influx of slow-reacting fibers, block or delay the forward conduction in the atrioventricular node reentry pathway, and large doses may also block or delay the forward and reverse conduction of the bypass pathway; in addition, it also has a short-term and strong effect of enhancing the vagus nerve, thereby terminating arrhythmias caused by atrioventricular node reentry and bypass reentry mechanisms.
More
It is a coenzyme that improves the body's metabolism and participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotides in the body. It is also the main source of energy in the body. When energy is needed for absorption, secretion, muscle contraction and biochemical synthesis reactions, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time. Animal experiments can inhibit the slow calcium ion influx of slow-reacting fibers, block or delay the forward conduction in the atrioventricular node reentry pathway, and large doses may also block or delay the forward and reverse conduction of the bypass pathway; in addition, it also has a short-term and strong effect of enhancing the vagus nerve, thereby terminating arrhythmias caused by atrioventricular node reentry and bypass reentry mechanisms. |
51963-61-2 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Oxytocin |
It stimulates the contraction of uterine smooth muscles, simulates the contraction of uterus during normal delivery, and causes cervical dilation; it stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secretion from the mammary gland.
More
It stimulates the contraction of uterine smooth muscles, simulates the contraction of uterus during normal delivery, and causes cervical dilation; it stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secretion from the mammary gland. |
50-56-6 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Oxytocin |
1. It stimulates the contraction of uterine smooth muscles, simulating the contraction of the uterus during normal childbirth, causing the cervix to dilate. The uterus's response to oxytocin gradually increases during pregnancy and reaches a peak at full term. 2. It stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secreted by the mammary gland.
More
1. It stimulates the contraction of uterine smooth muscles, simulating the contraction of the uterus during normal childbirth, causing the cervix to dilate. The uterus's response to oxytocin gradually increases during pregnancy and reaches a peak at full term. 2. It stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secreted by the mammary gland. |
50-56-6 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Oxytocin |
It stimulates the contraction of uterine smooth muscles, simulates the contraction of uterus during normal delivery, and causes cervical dilation; it stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secretion from the mammary gland.
More
It stimulates the contraction of uterine smooth muscles, simulates the contraction of uterus during normal delivery, and causes cervical dilation; it stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secretion from the mammary gland. |
50-56-6 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Heparin sodium |
Because this product has the physical and chemical characteristics of strong negative charge, it can interfere with many links of the blood coagulation process and has anticoagulant effect in vivo and in vitro. Its mechanism of action is relatively complex, mainly through binding with antithrombin III (AT-III), thereby enhancing the latter's inhibitory effect on activated coagulation factors II, IX, X, XI and XII. Its consequences involve preventing platelet aggregation and destruction, hindering the formation of coagulation activating enzymes; preventing prothrombin from turning into thrombin; inhibiting thrombin, thereby preventing fibrinogen from turning into fibrin.
More
Because this product has the physical and chemical characteristics of strong negative charge, it can interfere with many links of the blood coagulation process and has anticoagulant effect in vivo and in vitro. Its mechanism of action is relatively complex, mainly through binding with antithrombin III (AT-III), thereby enhancing the latter's inhibitory effect on activated coagulation factors II, IX, X, XI and XII. Its consequences involve preventing platelet aggregation and destruction, hindering the formation of coagulation activating enzymes; preventing prothrombin from turning into thrombin; inhibiting thrombin, thereby preventing fibrinogen from turning into fibrin. |
9041-08-1 | 82 |